1/7 Excited to talk about some of the amazing science we discovered about #meningioma#biology at @LabRaleigh. Humbled to be the lead author on this massive, collaborative project. It was a herculean effort only possible thanks to the efforts of so many people! #braintumor#BTSM
The Vasudevan Lab makes its first twitter post: Excited to share our preprint looking at functional interactions between NF tumor suppressors https://t.co/eKTVULnyZd
Super excited for this next step in my physician-scientist journey! And incredibly grateful for all the people who have supported me along the way. Wouldn't be here without my time at @LabRaleigh.
Today, we’re introducing a new model that eliminates accept/reject decisions.
By publishing every paper with eLife reviews as a Reviewed Preprint, we plan to restore autonomy to authors, ensuring that they will be judged by what, not where, they publish. https://t.co/OAsiOVFStI
Our collaboration with the Schmitt lab @MSK_RadOnc is online! Happy to have helped with some Hedgehog things and some bioinformatic things with @DrHVasu to elucidate how lncRNAs can influence brain cancer stem cells. https://t.co/eGDcTujAvg
Federally funded research should be freely accessible to the American public. From environmental justice to cancer breakthroughs to more sustainable farming, immediate access to America’s research jumpstarts innovation everywhere.
https://t.co/CxGMMIWjX1
Just over a year ago, I read a paper which showed that when private equity buys nursing homes, death rates go up 10%. I was a med student at Stanford, but I halted my studies to investigate. Today, that investigation was published in @NewYorker https://t.co/cQzbWggk46
BREAKING: White House issues new policy that will require, by 2026, all federally-funded research results to be freely available to public without delay, ending longstanding ability of journals to paywall results for up to 1 year. Coverage coming on @ScienceInsider.
Very happy to share our pre-print reporting interactions between NF1 and NF2 driving Schwann cell tumor de-differentiation and treatment resistance. Lead author @DrHVasu of the eponymous Vasudevan Lab at @NeurosurgUCSF@UCSFCancer in the driver's seat! https://t.co/0r3DjVvWXW